CN108034712A - Diagnosisof Kawasaki Disease with Coronary Artery Involvement diagnosis of risk and detection kit - Google Patents
Diagnosisof Kawasaki Disease with Coronary Artery Involvement diagnosis of risk and detection kit Download PDFInfo
- Publication number
- CN108034712A CN108034712A CN201711452354.XA CN201711452354A CN108034712A CN 108034712 A CN108034712 A CN 108034712A CN 201711452354 A CN201711452354 A CN 201711452354A CN 108034712 A CN108034712 A CN 108034712A
- Authority
- CN
- China
- Prior art keywords
- kawasaki disease
- genes
- reagent
- associated gene
- coronary artery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to biological technical field, specifically provides a kind of purposes of Kawasaki disease hazardous substance as biomarker in the kit for Diagnosisof Kawasaki Disease with Coronary Artery Involvement risk assessment is prepared, and the Kawasaki disease hazardous substance is selected from following one or more：The protein of mRNA, the Kawasaki disease associated gene or its fragment coding that Kawasaki disease associated gene or its fragment, the Kawasaki disease associated gene or its fragment are transcribed；Wherein, the Kawasaki disease associated gene includes following 1 ~ 8：CD247 genes, TNFRSF1A genes, SMAD2 genes, MMP9 genes, BMP2 genes, ACVR2B genes, CXCL14 genes, the CD14 genes present invention can assess patients with Kawasaki disease and the Diagnosisof Kawasaki Disease with Coronary Artery Involvement risk of suspicious infant, so that medical staff can take corresponding treatment or precautionary measures early.
Description
Technical field
The present invention relates to biological technical field, more particularly to a kind of Diagnosisof Kawasaki Disease with Coronary Artery Involvement diagnosis of risk and detection
Kit.
Background technology
Kawasaki disease (Kawasaki disease, KD) is a kind of unknown children's systemic vasculitis of cause of disease, is that children obtain
Property cardiopathic most commonly encountered diseases because one of, clinical manifestation is persistent fever, fash, cervical lymph node enlargement, and conjunctive bulbi fills
Blood, acra and alteration in oral mucous membrane etc..
As treated not in time, the infant of a quarter is by concurrent coronary artery pathological changes.The infant of this quarter can claim
For high-risk Kawasaki disease coronary artery infant.The coronaritis that KD triggers may cause vascular remodeling and reconstruction, cause endothelium to increase
Raw and hemadostewnosis, blood vessel substantially thicken.And the coronal lesion of continuation that KD triggers has the very high cardiac complication general
Rate, including thrombosis or narrow caused myocardial infarction.
The generation of coronary artery pathological changes can be prevented by generally carrying out medication in Kawasaki disease is fallen ill 10 days, but be fallen ill 10 days
Medication afterwards, effect be not notable.Therefore, diagnosing early for Kawasaki disease has important meaning for the coronary artery pathological changes for preventing its initiation
Justice, especially for high-risk Kawasaki disease coronary artery disease infant.
The Primary Reference of current diagnosis according to the clinical manifestation for being patient and blood routine detection data, as leucocyte, in
Cell concentration, hemoglobin concentration, the blood such as property granulocyte, staff cell, lymphocyte, monocyte, eosinophils are small
Plate concentration, C reactive protein concentration, alanine aminotransferase, glutamyl transferase, and the life of the physiology such as erythrocyte sedimentation rate (ESR)
Change index.
Above-mentioned clinical indices are all that Kawasaki disease has fallen ill or even triggered during coronary artery pathological changes and showed, therefore, root
It is difficult to timely diagnose Kawasaki disease and prevention coronary artery pathological changes according to These parameters, it is also difficult to find Kawasaki disease coronary artery disease
The high-risk children of change.
The content of the invention
In view of the foregoing deficiencies of prior art, it is an object of the invention to provide one kind to be used for Kawasaki disease coronary artery
The kit of lesion risk assessment, it can be estimated that the Diagnosisof Kawasaki Disease with Coronary Artery Involvement risk of Patients with Kawasaki Disease or suspicious infant, with
Just corresponding treatment or precautionary measures are taken early.
It is coronal for Kawasaki disease in preparation as biomarker that first aspect present invention provides Kawasaki disease hazardous substance
Purposes in the kit of arterial disease risk assessment, the Kawasaki disease hazardous substance are selected from following one or more：Kawasaki disease
Associated gene or its fragment, the mRNA of the Kawasaki disease associated gene or the transcription of its fragment, the Kawasaki disease associated gene or its
The protein of fragment coding, wherein, the Kawasaki disease associated gene includes following 1~8：
CD247 genes, TNFRSF1A genes, SMAD2 genes, MMP9 genes, BMP2 genes, ACVR2B genes, CXCL14
Gene, CD14 genes.
In a kind of possible implementation, the Kawasaki disease associated gene or its fragment are to associate SNP containing Kawasaki disease
The nucleotide fragments in site.
It is coronal for Kawasaki disease in preparation that the second aspect of the present invention provides the reagent for being used to detect Kawasaki disease hazardous substance
Purposes in the kit of arterial disease risk assessment, the Kawasaki disease hazardous substance are selected from following one or more：
MRNA, the Kawasaki of Kawasaki disease associated gene or its fragment, the Kawasaki disease associated gene or the transcription of its fragment
The protein of sick associated gene or its fragment coding；Wherein,
The Kawasaki disease associated gene includes following 1~8：
CD247 genes, TNFRSF1A genes, SMAD2 genes, MMP9 genes, BMP2 genes, ACVR2B genes, CXCL14
Gene, CD14 genes.
In a kind of possible implementation, the reagent for being used to detect Kawasaki disease hazardous substance is used to obtain Kawasaki disease
Associate SNP site.
In a kind of possible implementation, the reagent for being used to detect Kawasaki disease hazardous substance is in following reagent
It is any：
Reagent needed for the PCR amplification of mutational site, reagent needed for ARMs augmentation detections, reagent, life needed for blend curve amplification
Reagent needed for thing chip array, reagent needed for Sanger sequencings, reagent needed for high-flux sequence.
In a kind of possible implementation, the reagent for being used to detect Kawasaki disease related substances includes the Kawasaki disease
Associated gene or the corresponding primer of its fragment, probe；
Wherein described probe is specially the derivative of biotin, fluorescence probe or fluorescence probe, and the fluorescence probe spreads out
Biology includes any of FAM, TET, JOE, HEX, ROX, AlexaFour 488, Quasar670, Texas Red, Cy3.
In a kind of possible implementation, the reagent for being used to detect Kawasaki disease related substances is used to detect subject
The reagent of Kawasaki disease related substances in biological sample；Wherein, subject's biological sample is selected from any one of following：
The peripheral blood of subject, urine, saliva, in mouth epithelial cells.
The third aspect of the present invention, there is provided a kind of kit for Diagnosisof Kawasaki Disease with Coronary Artery Involvement risk assessment, it is special
Sign is, including the reagent for being used to detect Kawasaki disease related substances.
Further, the kit further includes the standard sample of the single nucleotide polymorphism of Kawasaki disease associated gene.
The fourth aspect of the present invention, there is provided a kind of computer-readable recording medium of storage program, it is described computer-readable
Storage medium includes instruction, when described instruction is computer-executed so that the computer performs following steps：
(1) subject's Kawasaki disease associated gene or the nucleotide sequence information of its fragment are received；Wherein, the Kawasaki disease closes
Symbasis is because including following 1~8：
CD247 genes, TNFRSF1A genes, SMAD2 genes, MMP9 genes, BMP2 genes, ACVR2B genes, CXCL14
Gene, CD14 genes；
(2) according to assessment models at least to the nucleotide sequence information of subject's Kawasaki disease associated gene or its fragment
Assessed, judge whether the subject is the high-risk person of Diagnosisof Kawasaki Disease with Coronary Artery Involvement.
In a kind of possible implementation, the Kawasaki disease associated gene or its fragment are to associate SNP containing Kawasaki disease
The nucleotide fragments in site.
In a kind of possible implementation, the assessment models are the Kawasaki disease associated genes according to patients with Kawasaki disease
What the nucleotide sequence information of nucleotide sequence information and the Kawasaki disease associated gene of non-patients with Kawasaki disease was drawn, wherein, it is described
Patients with Kawasaki disease includes Kawasaki disease coronary artery on-expansible patient and Coronary Artery Dilatation in Kawasaki Disease patient.
In a kind of possible implementation, the river using the caret bags in R language to the sample of some known mutations types
The corresponding training dataset of rugged disease associated gene is trained, and obtains the assessment models used in R language environments.
In a kind of possible implementation, using the LAD methods in " train " function in caret bags come to being obtained
The training dataset obtained is trained acquisition assessment models.
Compared with prior art, the present invention has the advantages that：
Provided by the present invention for detecting the reagent of Kawasaki disease hazardous substance, being commented for Diagnosisof Kawasaki Disease with Coronary Artery Involvement risk
The kit estimated, it can be estimated that patients with Kawasaki disease and the Diagnosisof Kawasaki Disease with Coronary Artery Involvement risk of suspicious infant, so that medical care
Personnel can take corresponding treatment or precautionary measures early.
Brief description of the drawings
Fig. 1 is a kind of assessment mould calculated for assessing Diagnosisof Kawasaki Disease with Coronary Artery Involvement risk provided in an embodiment of the present invention
The flow diagram of type.
Embodiment
The main reason for Kawasaki disease is acquired heart disease in children, the Kawasaki disease case more than 80% come across 6 months to 4
In the age in year.The reason for Kawasaki disease is unknown, although and it is infectious agent (infectious agent) to suspect, lose
Pass and environment seems also to work in the disease.Kawasaki disease is diagnosed and can only realized by the combination of Clinical symptoms at present,
Therefore quick diagnosis is impossible.Unfortunately, delayed diagnosis (and caused delay in the appropriate treatment of application) causes
The probability increase of severe complication.In fact, coronary aneurysm is formed in the patient of up to 20% untreated, and only
5% patient through treatment forms such aneurysm.Therefore, Kawasaki disease fast diagnosis method and Diagnosisof Kawasaki Disease with Coronary Artery Involvement
Methods of risk assessment has very important meaning in clinical diagnosis field.
Whole-genome association (Genome-wide association study, GWAS) has been successfully used to multiple
Miscellaneous disease medium-high frequency hereditary variation.High frequency single nucleotide polymorphism (the Single Nucleotide that GWAS can be detected
Polymorphisms, SNP) it can only explain sub-fraction hereditary variability.With the development of high throughput sequencing technologies, people is studied
Member has found that more and more evidences support low frequency to be mutated the effect in complex inheritance disease.However, widespread practice is high
The variation of frequency and low frequency is associated analysis respectively.
The present invention is coronal dynamic for Kawasaki disease using a kind of method of the Conjoint Analysis of high and low frequency variation comprehensive effect
The genome sequence of arteries and veins expansion patient, Kawasaki disease coronary artery on-expansible patient and non-patients with Kawasaki disease are associated analysis,
It is found that and Kawasaki disease, particularly the closely related gene of Coronary Artery Dilatation in Kawasaki Disease, is referred to as Kawasaki disease associated gene.River
Rugged disease associated gene specifically includes CD247 genes, TNFRSF1A genes, SMAD2 genes, MMP9 genes, BMP2 genes, ACVR2B
Gene, CXCL14 genes, CD14 genes, the particularly single nucleotide polymorphism and Kawasaki disease of these genes, Kawasaki disease are coronal dynamic
Arteries and veins expansion is closely related, can be coronal according to the early diagnosis of 1~8 progress Kawasaki disease in this 8 genes and Kawasaki disease
Arterial disease risk assessment.
Before the specific embodiment of the invention is further described, it should be appreciated that protection scope of the present invention is not limited to down
State specific specific embodiment；It is also understood that the term used in the embodiment of the present invention is specific specific in order to describe
Embodiment, the protection domain being not intended to be limiting of the invention；In description of the invention and claims, unless in text
In addition explicitly point out, singulative "one", " one " and " this " include plural form.
When embodiment provides number range, it should be appreciated that except non-invention is otherwise noted, two ends of each number range
Any one numerical value can be selected between point and two endpoints.Unless otherwise defined, in the present invention all technologies for using and
Scientific terminology is identical with the normally understood meaning of those skilled in the art of the present technique.Except used in embodiment specific method, equipment,
Outside material, according to grasp of the those skilled in the art to the prior art and the record of the present invention, it can also use and this
Any method, equipment and the material of the similar or equivalent prior art of method, equipment described in inventive embodiments, material come real
The existing present invention.
Unless otherwise stated, disclosed in this invention experimental method, detection method, preparation method using this technology lead
Molecular biology, biochemistry, chromatin Structure and the analysis of domain routine, analytical chemistry, cell culture, recombinant DNA technology and
The routine techniques of association area.These technologies existing perfect explanation in the prior art, for details, reference can be made to Sambrook etc.
MOLECULAR CLONING：A LABORATORY MANUAL, Second edition, Cold Spring Harbor
Laboratory Press, 1989and Third edition, 2001；Ausubel etc., CURRENT PROTOCOLS IN
MOLECULAR BIOLOGY, John Wiley＆Sons, New York, 1987and periodic updates；the
Series METHODS IN ENZYMOLOGY, Academic Press, San Diego；Wolffe, CHROMATIN
STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998；METHODS IN
ENZYMOLOGY, Vol.304, Chromatin (P.M.Wassarman and A.P.Wolffe, eds.), Academic
Press, San Diego, 1999；With METHODS IN MOLECULAR BIOLOGY, Vol.119, Chromatin
Protocols (P.B.Becker, ed.) Humana Press, Totowa, 1999 etc..
Hereafter the technical solution of the embodiment of the present invention is further illustrated with specific embodiment 1.
Embodiment 1
For 116 patients with Kawasaki disease (including Coronary Artery Dilatation in Kawasaki Disease patient and Kawasaki disease coronary artery on-expansible
Patient) and 10 healthy volunteers, 1~2 milliliter of peripheral blood is respectively taken in EDTA anticoagulant tubes, extracts genomic DNA, wherein 1ug
DNA is prepared for high throughput library, and is multiplied by using Roche targeting enrichment sequencings, target area sequencing depth 150.Survey
Ordinal number is obtained according to by Quality Control and the comparison of BWA softwares, the processing of Picard and GATK software tools, and the processing of GATK VQSR programs
The genome nucleotide sequence information of each sample is obtained, and then learns the SNP site catastrophe of each sample.
It is as shown in Figure 1, non-to Coronary Artery Dilatation in Kawasaki Disease patient and Kawasaki disease coronary artery using SKAT algorithm models
Expansion patient genome nucleotide sequence information (the SNP site catastrophe for including each sample) analyzed, find with
Coronary Artery Dilatation in Kawasaki Disease patient compares, and sharing 70 genes may be associated with Coronary Artery Dilatation in Kawasaki Disease patient.Adopt
With patients with Kawasaki disease (including Coronary Artery Dilatation in Kawasaki Disease patient and Kawasaki disease coronary artery on-expansible patient) and health aspiration
The genome nucleotide sequence information (the SNP site catastrophe for including each sample) of person is analyzed, and is found and healthy will
Hope person compares, and sharing 51 genes may be associated with patients with Kawasaki disease.After overlapping (overlap), 8 genes and Kawasaki are shared
Sick coronary artery expansion patient is associated, this 8 genes, that is, CD247 genes, TNFRSF1A genes, SMAD2 genes, MMP9 bases
Cause, BMP2 genes, ACVR2B genes, CXCL14 genes, CD14 genes.This 8 genes are related to coronary artery pathological changes excessive risk altogether
Polymorphic site 143.It should be noted that SKAT algorithm models, which are one kind, is used for single nucleotide polymorphism set (for example, base
Because or region) horizontal checkout algorithm model, for the pass between one group of rare (or common) variation and two points or quantitative phenotype
Connection, SKAT polymerize the individual scoring test statistics of SNP in SNP groups, and effectively calculate the horizontal p value of SNP collection, such as gene or region
Horizontal p value, while covariant is adjusted, such as principal component, to explain that population is layered.SKAT also allows to carry out power/sample size meter
Calculate, for implementation sequence association study.The conspicuousness score value of the mutation of each gene in the present embodiment is provided by SKAT softwares.
Next, assessment models of the structure for Diagnosisof Kawasaki Disease with Coronary Artery Involvement risk assessment, specific method are as follows：
Sample Kawasaki disease associated gene corresponding instruction of the caret bags in R language to some known mutations types can be utilized
Practice data set to be trained, obtain the assessment models used in R language environments.Specifically, it can use in caret bags
LAD methods in " train " function are trained acquisition assessment models to the training dataset obtained.
Under normal circumstances, in order to higher accuracy rate, 8 genes, that is, CD247 bases of 50 sample above can be used
Cause, TNFRSF1A genes, SMAD2 genes, MMP9 genes, BMP2 genes, ACVR2B genes, CXCL14 genes, CD14 genes
SNP mutation situation establishes assessment models as training dataset.Preferably, 8 bases of the sample of more than 60 may be selected
The SNP mutation situation of cause establishes assessment models as training dataset.Further, it may be selected described the 8 of 70 sample above
The SNP mutation situation of a gene establishes assessment models as training dataset.Yet further, 80 sample above may be selected
8 genes SNP mutation situation as training dataset, establish assessment models.As an example, the present embodiment is selected
The SNP mutation situation of 8 genes of 87 samples establishes assessment models as training dataset.
The caret bags in R language are initially entered, prepare training dataset, the training using " trainControl "
Data set is 8 genes, that is, CD247 genes of 75% sample in 116 samples, TNFRSF1A genes, SMAD2 genes,
MMP9 genes, BMP2 genes, ACVR2B genes, CXCL14 genes, the SNP mutation situation of CD14 genes.Can be to catastrophe
Carry out self-defined, such as be denoted as 0, if homozygous mutation is denoted as 1, if heterozygous mutant is denoted as 2 without mutation.Next selection
LAD methods in " train " function are trained the training dataset obtained.Default parameters, that is, cross validation is set
Number, is set to 10 times, obtains the assessment models used in R language environments in the present embodiment.
Using the SNP site catastrophe of remaining 25% sample in 116 samples as validation data set, utilize
" accuracy rate " index weighs the good and bad degree of the assessment models.
Specific method is：Into the caret bags in R language, open what obtained described used in R language environments
Assessment models, input the validation data set, and the validation data set is 8 of remaining 25% sample in 116 samples
A gene, that is, CD247 genes, TNFRSF1A genes, SMAD2 genes, MMP9 genes, BMP2 genes, ACVR2B genes, CXCL14
If the SNP mutation situation of gene, CD14 genes is denoted as 0, if homozygous mutation is denoted as 1, if heterozygous mutant without mutation
2 are denoted as, assessment is completed using " predict " function in caret bags.Sample directly can be judged excessive risk Kawasaki disease by the function
Coronary artery pathological changes sample or low-risk Diagnosisof Kawasaki Disease with Coronary Artery Involvement sample.
The true Diagnosisof Kawasaki Disease with Coronary Artery Involvement situation that the assessment result of acquisition and 29 samples are had determined carries out
Compare, sensitiveness 80%, specificity is 94%, accuracy rate 90%.Wherein, the sensitiveness refers in positive prediction result
The percentage of " true positives ", sensitiveness more show that the prediction model can detect the patient of " true positives " closer to 100%.Institute
The percentage that specificity refers in negative prediction result " true negative " is stated, specificity more shows the prediction mould closer to 100%
Type can exclude " false negative " patient.The accuracy rate refers in all prediction results the percentage of " true positives " and " true negative ",
Accuracy rate more shows that the model can detect excessive risk patient, can also detect low-risk patient closer to 100%.
However, remaining 25% sample in 116 samples is judged into coronary artery using Kobayashi clinical symptoms
Risk, sensitiveness is 14%, and specificity is 86%, accuracy rate 69%.
The above-described embodiments merely illustrate the principles and effects of the present invention, not for the limitation present invention.It is any ripe
Know the personage of this technology all can carry out modifications and changes under the spirit and scope without prejudice to the present invention to above-described embodiment.Cause
This, those of ordinary skill in the art is complete without departing from disclosed spirit and institute under technological thought such as
Into all equivalent modifications or change, should by the present invention claim be covered.
Claims (13)
1. Kawasaki disease hazardous substance is preparing the reagent for Diagnosisof Kawasaki Disease with Coronary Artery Involvement risk assessment as biomarker
Purposes in box,
The Kawasaki disease hazardous substance is selected from following one or more：
Kawasaki disease associated gene or its fragment, the mRNA of the Kawasaki disease associated gene or the transcription of its fragment, the Kawasaki disease close
Symbasis because or its fragment coding protein；Wherein,
The Kawasaki disease associated gene includes following 1~8：
CD247 genes, TNFRSF1A genes, SMAD2 genes, MMP9 genes, BMP2 genes, ACVR2B genes, CXCL14 genes,
CD14 genes.
2. purposes according to claim 1, it is characterised in that the Kawasaki disease associated gene or its fragment is contain Kawasaki
The nucleotide fragments of disease association SNP site.
3. preparing the reagent for Diagnosisof Kawasaki Disease with Coronary Artery Involvement risk assessment for the reagent for detecting Kawasaki disease hazardous substance
Purposes in box,
The Kawasaki disease hazardous substance is selected from following one or more：
Kawasaki disease associated gene or its fragment, the mRNA of the Kawasaki disease associated gene or the transcription of its fragment, the Kawasaki disease close
Symbasis because or its fragment coding protein；Wherein,
The Kawasaki disease associated gene includes following 1~8：
CD247 genes, TNFRSF1A genes, SMAD2 genes, MMP9 genes, BMP2 genes, ACVR2B genes, CXCL14 genes,
CD14 genes.
4. purposes according to claim 3, it is characterised in that the reagent for being used to detect Kawasaki disease hazardous substance is used for
Obtain Kawasaki disease association SNP site.
5. purposes according to claim 3, it is characterised in that the reagent for being used to detect Kawasaki disease hazardous substance is selected from
Any of following reagent：
Reagent needed for the PCR amplification of mutational site, reagent needed for ARMs augmentation detections, reagent, biological core needed for blend curve amplification
Reagent needed for chip arrays, reagent needed for Sanger sequencings, reagent needed for high-flux sequence.
6. purposes according to claim 3, it is characterised in that the reagent for being used to detect Kawasaki disease related substances includes
The Kawasaki disease associated gene or the corresponding primer of its fragment, probe；
Wherein described probe is specially the derivative of biotin, fluorescence probe or fluorescence probe, the derivative of the fluorescence probe
Including any of FAM, TET, JOE, HEX, ROX, AlexaFour 488, Quasar670, Texas Red, Cy3.
7. purposes according to claim 3, it is characterised in that the reagent for being used to detect Kawasaki disease related substances is used for
Detect the reagent of the Kawasaki disease related substances in subject's biological sample；Wherein, subject's biological sample is selected from following
One：
The peripheral blood of subject, urine, saliva, in mouth epithelial cells.
8. a kind of kit for Diagnosisof Kawasaki Disease with Coronary Artery Involvement risk assessment, it is characterised in that appoint including claim 2-8
In purposes described in one, the reagent for being used to detect Kawasaki disease related substances.
9. the kit according to claim 8 for Diagnosisof Kawasaki Disease with Coronary Artery Involvement risk assessment, it is characterised in that also
The standard sample of single nucleotide polymorphism including Kawasaki disease associated gene.
10. a kind of computer-readable recording medium of storage program, it is characterised in that the computer-readable recording medium includes
Instruction, when described instruction is computer-executed so that the computer performs following steps：
(1) subject's Kawasaki disease associated gene or the nucleotide sequence information of its fragment are received；Wherein, the Kawasaki disease association base
Because including following 1~8：
CD247 genes, TNFRSF1A genes, SMAD2 genes, MMP9 genes, BMP2 genes, ACVR2B genes, CXCL14 genes,
CD14 genes；
(2) at least the nucleotide sequence information of subject's Kawasaki disease associated gene or its fragment is carried out according to assessment models
Assessment, judges whether the subject is the high-risk person of Diagnosisof Kawasaki Disease with Coronary Artery Involvement.
11. the computer-readable recording medium of storage program according to claim 10, it is characterised in that the assessment mould
Type is to be associated according to the nucleotide sequence information of the Kawasaki disease associated gene of patients with Kawasaki disease with the Kawasaki disease of non-patients with Kawasaki disease
What the nucleotide sequence information of gene was drawn, wherein, the patients with Kawasaki disease include Kawasaki disease coronary artery on-expansible patient and
Coronary Artery Dilatation in Kawasaki Disease patient.
12. the computer-readable recording medium of storage program according to claim 10, it is characterised in that utilize R language
In caret bags the corresponding training dataset of Kawasaki disease associated gene of the sample of some known mutations types is trained, obtain
Obtain the assessment models used in R language environments.
13. the computer-readable recording medium of storage program according to claim 12, it is characterised in that using caret
LAD methods in " train " function in bag are trained acquisition assessment models to the training dataset obtained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711452354.XA CN108034712A (en) | 2017-12-28 | 2017-12-28 | Diagnosisof Kawasaki Disease with Coronary Artery Involvement diagnosis of risk and detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711452354.XA CN108034712A (en) | 2017-12-28 | 2017-12-28 | Diagnosisof Kawasaki Disease with Coronary Artery Involvement diagnosis of risk and detection kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108034712A true CN108034712A (en) | 2018-05-15 |
Family
ID=62097670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711452354.XA Pending CN108034712A (en) | 2017-12-28 | 2017-12-28 | Diagnosisof Kawasaki Disease with Coronary Artery Involvement diagnosis of risk and detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108034712A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112159472A (en) * | 2020-09-28 | 2021-01-01 | 上海千贝医疗科技有限公司 | Antibody, reagent and kit for assessing treatment effect of Kawasaki disease and application of antibody, reagent and kit |
| CN114073770A (en) * | 2020-08-21 | 2022-02-22 | 广州市妇女儿童医疗中心 | Application of MCM8-cGAS-STING-I type interferon signal channel as disease target |
| CN116773825A (en) * | 2022-08-19 | 2023-09-19 | 天津云检医学检验所有限公司 | Blood biomarkers and methods for diagnosing acute kawasaki disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101778864A (en) * | 2007-09-06 | 2010-07-14 | 艾博特股份有限两合公司 | Proteic Delicious peptide (BMP)-binding domains and the function fragment and their purposes of repellency guiding molecule (RGM) protein families |
| CN106062004A (en) * | 2013-12-17 | 2016-10-26 | 科马布有限公司 | Ligands specifically binding to human targets of interest |
-
2017
- 2017-12-28 CN CN201711452354.XA patent/CN108034712A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101778864A (en) * | 2007-09-06 | 2010-07-14 | 艾博特股份有限两合公司 | Proteic Delicious peptide (BMP)-binding domains and the function fragment and their purposes of repellency guiding molecule (RGM) protein families |
| CN106062004A (en) * | 2013-12-17 | 2016-10-26 | 科马布有限公司 | Ligands specifically binding to human targets of interest |
Non-Patent Citations (5)
| Title |
|---|
| GUO-BING WANG等: "A regulatory polymorphism in promoter region of TNFR1 gene is associated with Kawasaki disease in Chinese individuals", 《HUMAN IMMUNOLOGY》 * |
| 朱丹颖等: "靶向捕获测序技术检测川崎病冠状动脉损害易感基因研究", 《中华儿科杂志》 * |
| 毛敏: "伴冠状动脉病变的川崎病儿童临床特点分析", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 王伟迪等: "《妇产与儿科常见病治疗学》", 31 May 2017, 吉林科学技术出版社 * |
| 王晓华等: "MMP-9、AECA、ANCA蛋白在川崎病外周血的表达及其与冠状动脉损害的关系", 《山东医药》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114073770A (en) * | 2020-08-21 | 2022-02-22 | 广州市妇女儿童医疗中心 | Application of MCM8-cGAS-STING-I type interferon signal channel as disease target |
| WO2022037679A1 (en) * | 2020-08-21 | 2022-02-24 | 广州市妇女儿童医疗中心 | Use of mcm8-cgas-sting-i-type interferon signal pathway as disease target |
| CN112159472A (en) * | 2020-09-28 | 2021-01-01 | 上海千贝医疗科技有限公司 | Antibody, reagent and kit for assessing treatment effect of Kawasaki disease and application of antibody, reagent and kit |
| CN116773825A (en) * | 2022-08-19 | 2023-09-19 | 天津云检医学检验所有限公司 | Blood biomarkers and methods for diagnosing acute kawasaki disease |
| CN116773825B (en) * | 2022-08-19 | 2023-12-01 | 天津云检医学检验所有限公司 | Blood biomarkers and methods for diagnosing acute Kawasaki disease |
| WO2024037387A1 (en) * | 2022-08-19 | 2024-02-22 | Tianjin Yunjian Medical Technology Co., Ltd. | Blood biomarkers and methods for diagnosis of acute kawasaki disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gasparetto et al. | Transcription and DNA methylation patterns of blood-derived CD8+ T cells are associated with age and inflammatory bowel disease but do not predict prognosis | |
| Shadrina et al. | Varicose veins of lower extremities: Insights from the first large-scale genetic study | |
| CN104232778B (en) | Determine the method and device of fetus haplotype and chromosomal aneuploidy simultaneously | |
| JP2017063794A (en) | Size-based analysis of fetal dna fraction in maternal plasma | |
| CN105256051A (en) | Probe set and reagent kit used for detecting pathopoiesia/susceptibility genes of congenital megacolon and relative syndromes | |
| JP2018143178A (en) | Genetic risk detection method for cardiovascular disease | |
| JP2018157776A (en) | Method for detecting hereditary risk of metabolic disease | |
| Graham et al. | Somatic mosaicism of sex chromosomes in the blood and brain | |
| CN105442052A (en) | Deoxyribonucleic acid (DNA) library for detecting disease causing genes of aoreic dissection diseases and application thereof | |
| CN112088220B (en) | Surrogate markers and methods for tumor mutation load determination | |
| CN105506115A (en) | DNA library for detection and diagnosis of hereditary cardiomyopathy causing genes and application thereof | |
| CN108034712A (en) | Diagnosisof Kawasaki Disease with Coronary Artery Involvement diagnosis of risk and detection kit | |
| AU2020364225B2 (en) | Fragment size characterization of cell-free DNA mutations from clonal hematopoiesis | |
| WO2013080227A1 (en) | Genetic variants useful for risk assessment of arterial disease | |
| CN115029431B (en) | Type 2 diabetes gene detection kit and type 2 diabetes genetic risk assessment system | |
| Sukcharoen et al. | IgA nephropathy genetic risk score to estimate the prevalence of IgA nephropathy in UK Biobank | |
| Szczerbiński et al. | Efficacy of family history, genetic risk score, and physical activity in assessing the prevalence of type 2 diabetes | |
| Liu et al. | Admixture mapping identifies genetic regions associated with blood pressure phenotypes in African Americans | |
| US20200347461A1 (en) | Phenotypic age and dna methylation based biomarkers for life expectancy and morbidity | |
| US20170145501A1 (en) | Apparatus and methods of using of biomarkers for predicting tnf-inhibitor response | |
| CN116287204A (en) | Application of mutation condition of detection characteristic gene in preparation of venous thromboembolism risk detection product | |
| CN103911439A (en) | Analyzing method and application of differential expression gene of systemic lupus erythematosus hydroxymethylation status | |
| CN109055547B (en) | Biomarker for evaluating aortic dissection risk and application thereof | |
| WO2022156610A1 (en) | Prediction tool for determining sensitivity of liver cancer to drug and long-term prognosis of liver cancer on basis of genetic testing, and application thereof | |
| CN106119406B (en) | Genotyping diagnostic kit for multiple granulomatous vasculitis and arteriolositis and using method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180515 |